BSA as a nanocarriers delivering Mycophenolic Acid

DODES TRAIAN, MARTÍN; PÉREZ, OSCAR E; MARTINEZ, KARINA D; SEPÚLVEDA CS; CASTAÑEDA CATAÑA, MAYRA ALEJANDRA; CARLUCCI, MARÍA JOSEFINA

Grenoble

Workshop; ESONN 2019 Session B; 2019

European School on Nanociences and Nanotechnologies

Viral hemorrhagic fevers (HF) are zoonoses able to cause dramatic and devastating local outbreaks in man. The ethological agents are four very different types of RNA viruses classified in the families Arenaviridae, Bunyaviridae, Filoviridae and Flaviviridae. These viruses can often produce a subclinical infection or a mild febrile syndrome, but the more severe forms of hemorrhagic disease are associated with extremely high morbidity and mortality. Despite of this threat for human health and although different types of compounds were evaluated for HF inhibition, no specific and safe chemotherapy for any viral HF is currently available for clinical use.The emergence of antiviral drug-resistant mutants is the traffic jam that current antiviral therapies suffer.  An ideal therapeutic target to prevent drug-resistance development are host factors that are crucial for the viral infective cycle. Alternative routes or secret paths become the key to escape traffic congestion. These new routes might be reached by improving antiviral drugs pharmacokinetics using a special car to transport drugs towards its molecular target.  Albumin nanoparticles are emerging as a platform for drug loading and targeting to improve pharmacokinetic profiles of organic molecules, peptides or even protein-based drugs.